Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 107, Issue 9, 2013, Pages 545-549

  Gomes, C ^a   Ruiz, L ^a   Pons, M J ^a   Ochoa, T J ^b,c   Ruiz, J ^a  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibiotic resistance; Diarrhoea; Efflux pumps; Escherichia coli; Rifaximin

Indexed keywords

ARGININE; PHENYL ARGININE BETA NAPHTHYLAMINE; RIFAMPICIN; RIFAXIMIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMENSAL ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERU;

ANTIBIOTIC RESISTANCE; DIARRHOEA; EFFLUX PUMPS; ESCHERICHIA COLI; RIFAXIMIN;

ANTI-BACTERIAL AGENTS; DIARRHEA; DIPEPTIDES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; RIFAMYCINS;

EID: 84886921315     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/trt059     Document Type: Article

References (27)

1. The United Nations Children's Fund/World Health Organization. Diarrhoea: Why children are still dying and what can be done. Geneva, Switzerland: WHO; 2009.
2. Huicho L, Trelles M, Gonzales F. National and sub-national under-five mortality profiles in Peru: a basis for informed policy decisions. BMC Public Health 2006;6:173-82.
3. Ochoa TJ. Diarrea producida por Escherichia coli. Rev Peru Enferm Infec Trop 2006;5:17-21.
4. Ochoa TJ, Mercado E, Durand D et al. Frequency and pathotypes of diarrheagenic Escherichia coli in Peruvian children with and without diarrhea [in Spanish]. Rev Peru Med Exp Salud Publica 2011;28:13-20.
5. Adachi JA, Ericsson CD, Jiang ZD et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travellers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003;37:1165-71.
6. Pons MJ, Mosquito S, Ochoa TJ et al. Levels of quinolones resistance and otherantimicrobial in non-pathogenic Escherichia coli strains in children from the periurban area of Lima, Peru. Rev Peru Med Exp Salud Publica 2012;29:82-6.
7. Sierra JM, Ruiz J, Navia MM et al. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob Agents Chemother 2001;45:643-4.
8. Anonymus. Guia para el abordaje de las enfermedades infecciosasmás comunes de la infancia y la desnutrición. 2009; Managua, Nicaragua.
9. DuPont HL, Ericsson CD, Farthing MJ et al. Expert reviewof the evidence base for self-therapy of travelers' diarrhea. J Travel Med 2009;16:161-71.
10. DuPont HL. Biologic properties and clinical uses of rifaximin. Expert Opin Pharmacother 2011;12:293-302.
11. Sierra JM,NaviaMM, VargasMet al. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother 2001;47:904-5.
12. Ruiz J, Mensa L, O'Callaghan C et al. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn Microbiol Infect Dis 2007;59:473-5.
13. Ruiz J, Mensa L, Pons MJ et al. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother 2008;61:1016-9.
14. Pons MJ, Mensa L, Gascón J et al. Fitness and molecular mechanismsof resistance to rifaximin in in vitro selected Escherichia coli mutants. Microb Drug Resist 2012;18:376-9.
15. Severinov K, Soushko M, Goldfarbs A et al. Newrifampicin-resistant and streptolydigin-resistant mutants in the b subunit of Escherichia coli RNA polymerase. J Biol Chem 1993;268:14820-5.
16. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-A vision for applied use. Biochem Pharmacol 2006;71:910-8.
17. Li B, Yao Q, Pan X et al. Artesunate enhances the antibacterial effect of b-lactam antibiotics against Escherichia coli by increasing antibiotic accumulation via inhibition of the multidrug efflux pump system AcrAB-TolC. J Antimicrob Chemother 2011;66:769-77.
18. Pannek S, Higgins PG, Steinke P et al. Multidrug efflux inhibition in Acinetobacterbaumannii: comparisonbetween 1-(1-naphthylmethyl)- piperazine andphenyl-arginine-b-naphthylamide. JAntimicrobChemother 2006;57:970-4.
19. Kothary V, Scherl EJ, Bosworth B et al. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-b- Naphthylamide-Inhibitable efflux pumps. Antimicrob Agents Chemother 2013;57:811-7.
20. Gomes C, Pons MJ, Magallon-Tejada A et al. In vitro development and analysis of Escherichia coli and Shigella boydii azithromycin-resistant mutants. Microb Drug Resist 2013;19:88-93.
21. Sáenz Y, Ruiz J, Zarazaga M et al. Effect of the efflux pump inhibitor Phe-Arg-b-naphthylamide on the MIC values of the quinolones, tetracycline and chloramphenicol, in Escherichia coli isolates of different origin. J Antimicrob Chemother 2004;53:544-5.
22. Baysarowich J, Koteva K, HughesDW. Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr. Proc Natl Acad Sci 2008;105:4886-91.
23. Ochoa TJ, Ecker L, Barletta Fet al. Age-related susceptibility to infection with diarrheagenic Escherichia coli in infants from peri-urban areas of Lima, Peru. Clin Infect Dis 2009;49:1694-702.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement M100-S21.Wayne, Pensylvania: CLSI; 2011.
25. Mushtaq S, Hopkins KL, Richardson JF et al. In vitro activity of rifaximin against Escherichia coli with prevalent ESBLs and carbapenemases. Clin Microbiol Infect 18:330.
26. Jiang ZD, Ke S, Palazzini E et al. In vitroactivity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-6.
27. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts by Escherichia coli. J Bacteriol 1997;179:2512-8.